Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Hansoh Pharmaceutical Group Company Company

3692.HK
KYG549581067
A2PLRC

Price

20.15
Today +/-
+0.12
Today %
+4.63 %
P

Hansoh Pharmaceutical Group Company stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Hansoh Pharmaceutical Group Company stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Hansoh Pharmaceutical Group Company stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Hansoh Pharmaceutical Group Company stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Hansoh Pharmaceutical Group Company's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Hansoh Pharmaceutical Group Company Stock Price History

DateHansoh Pharmaceutical Group Company Price
10/18/202420.15 undefined
10/17/202419.24 undefined
10/16/202418.60 undefined
10/15/202418.93 undefined
10/14/202418.95 undefined
10/10/202419.44 undefined
10/9/202418.67 undefined
10/8/202418.76 undefined
10/7/202419.25 undefined
10/4/202419.52 undefined
10/3/202418.98 undefined
10/2/202419.75 undefined
9/30/202418.92 undefined
9/27/202419.53 undefined
9/26/202418.11 undefined
9/25/202417.44 undefined
9/24/202417.67 undefined
9/23/202418.11 undefined

Hansoh Pharmaceutical Group Company Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hansoh Pharmaceutical Group Company, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hansoh Pharmaceutical Group Company from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hansoh Pharmaceutical Group Company’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hansoh Pharmaceutical Group Company. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hansoh Pharmaceutical Group Company’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hansoh Pharmaceutical Group Company’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hansoh Pharmaceutical Group Company’s growth potential.

Hansoh Pharmaceutical Group Company Revenue, EBIT and net profit per share

DateHansoh Pharmaceutical Group Company RevenueHansoh Pharmaceutical Group Company EBITHansoh Pharmaceutical Group Company Net Income
2029e17.61 B undefined0 undefined0 undefined
2028e16.25 B undefined5.61 B undefined0 undefined
2027e14.91 B undefined5.25 B undefined0 undefined
2026e14.1 B undefined4.48 B undefined4.31 B undefined
2025e12.65 B undefined3.88 B undefined3.8 B undefined
2024e12.32 B undefined4.22 B undefined3.81 B undefined
202310.1 B undefined2.65 B undefined3.28 B undefined
20229.38 B undefined2.57 B undefined2.58 B undefined
20219.94 B undefined2.96 B undefined2.71 B undefined
20208.69 B undefined2.78 B undefined2.57 B undefined
20198.68 B undefined2.8 B undefined2.56 B undefined
20187.72 B undefined2.26 B undefined1.9 B undefined
20176.19 B undefined1.91 B undefined1.6 B undefined
20165.43 B undefined1.79 B undefined1.48 B undefined

Hansoh Pharmaceutical Group Company Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
5.436.197.728.688.699.949.3810.112.3212.6514.114.9116.2517.61
-13.8624.8512.430.0914.33-5.577.6821.892.7111.495.748.988.38
92.6992.6492.1991.6090.7591.2390.7389.79------
5.045.737.127.957.899.068.519.07000000
1.791.912.262.82.782.962.572.654.223.884.485.255.610
32.9030.9529.2032.2232.0329.7827.3426.1934.2830.6731.7335.1734.49-
1.481.61.92.562.572.712.583.283.813.84.31000
-8.0619.3134.310.475.61-4.7626.8716.17-0.2913.59---
--------------
--------------
5.165.165.165.485.8865.936.02000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Hansoh Pharmaceutical Group Company Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Hansoh Pharmaceutical Group Company is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20162017201820192020202120222023
               
1.341.723.4914.5913.7218.9321.6224.86
1.571.371.61.552.743.253.533.21
0.170.841.070.730.470.530.140.11
353.05439.36479.66414.35298.73410.13447.89575.78
26.7841.5337.78161.0659.2854.3186129.84
3.464.426.6817.4517.2923.1825.8328.88
1.231.331.582.123.473.573.483.29
000028.39394.97653.65684.71
00000000
6.069.1810.484.579.8917.0433.42177.42
00000000
120.29117.63138.8500000
1.361.461.732.133.513.984.174.16
4.825.878.4119.5820.7927.163033.04
               
1115152525252
1.31.31.310.8414.0114.0213.9314.1
1.63.191.11.954.596.999.0311.67
75.3924.2770.43255.71-722.48-923.89-291136.92
00000000
2.974.522.4713.0417.8820.0922.6725.9
44.9198.79158.81192.85124.38248.33222.3163.76
0.750.851.031.461.882.21.921.97
1.020.283.324.590.680.560.460.53
00000000
00000.010.010.024.2
1.811.234.56.242.693.022.626.86
0000.010.083.824.360.1
34.65127.68242.69284.77121.81266.75350.66255.02
001.200.020.020.020.02
0.030.131.440.290.234.114.740.38
1.851.365.956.532.927.137.357.24
4.825.878.4119.5820.7927.2230.0333.15
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Hansoh Pharmaceutical Group Company provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Hansoh Pharmaceutical Group Company's financial health and stability.

Assets

Hansoh Pharmaceutical Group Company's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Hansoh Pharmaceutical Group Company must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Hansoh Pharmaceutical Group Company after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Hansoh Pharmaceutical Group Company's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
1.81.932.3133.13.32.95
119135156201233278344
0000000
-669-644-350291-806-747-629
-6-21-43-163-134-25377
3000000
311231306541590319324
1.251.42.073.332.392.582.74
-238-256-381-592-1,427-460-272
829-614-1,388-7,075-2,874-2,259-5,935
1.07-0.36-1.01-6.48-1.45-1.8-5.66
0000000
-0.0500-0.04-0.013.84-0.04
1.3009.533.17-0.04-0.06
-2.05-0.7307.99-1.043.42-0.82
-3,301.00-730.00-----
000-1,500-4,200-380-712
0.050.060.74.38-2.283.66-4.05
1,007.581,145.911,690.852,737.21962.832,117.032,468.38
0000000

Hansoh Pharmaceutical Group Company stock margins

The Hansoh Pharmaceutical Group Company margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hansoh Pharmaceutical Group Company. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hansoh Pharmaceutical Group Company.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hansoh Pharmaceutical Group Company's sales revenue. A higher gross margin percentage indicates that the Hansoh Pharmaceutical Group Company retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hansoh Pharmaceutical Group Company's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hansoh Pharmaceutical Group Company's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hansoh Pharmaceutical Group Company's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hansoh Pharmaceutical Group Company. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hansoh Pharmaceutical Group Company's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hansoh Pharmaceutical Group Company Margin History

Hansoh Pharmaceutical Group Company Gross marginHansoh Pharmaceutical Group Company Profit marginHansoh Pharmaceutical Group Company EBIT marginHansoh Pharmaceutical Group Company Profit margin
2029e89.78 %0 %0 %
2028e89.78 %34.49 %0 %
2027e89.78 %35.17 %0 %
2026e89.78 %31.73 %30.58 %
2025e89.78 %30.67 %30.01 %
2024e89.78 %34.28 %30.92 %
202389.78 %26.19 %32.44 %
202290.73 %27.34 %27.54 %
202191.24 %29.79 %27.31 %
202090.76 %32.03 %29.56 %
201991.6 %32.22 %29.45 %
201892.19 %29.21 %24.64 %
201792.64 %30.95 %25.79 %
201692.69 %32.89 %27.17 %

Hansoh Pharmaceutical Group Company Stock Sales Revenue, EBIT, Earnings per Share

The Hansoh Pharmaceutical Group Company earnings per share therefore indicates how much revenue Hansoh Pharmaceutical Group Company has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hansoh Pharmaceutical Group Company earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hansoh Pharmaceutical Group Company's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hansoh Pharmaceutical Group Company’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hansoh Pharmaceutical Group Company's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hansoh Pharmaceutical Group Company Revenue, EBIT and net profit per share

DateHansoh Pharmaceutical Group Company Sales per ShareHansoh Pharmaceutical Group Company EBIT per shareHansoh Pharmaceutical Group Company Earnings per Share
2029e2.97 undefined0 undefined0 undefined
2028e2.74 undefined0 undefined0 undefined
2027e2.51 undefined0 undefined0 undefined
2026e2.38 undefined0 undefined0.73 undefined
2025e2.13 undefined0 undefined0.64 undefined
2024e2.08 undefined0 undefined0.64 undefined
20231.68 undefined0.44 undefined0.54 undefined
20221.58 undefined0.43 undefined0.44 undefined
20211.66 undefined0.49 undefined0.45 undefined
20201.48 undefined0.47 undefined0.44 undefined
20191.59 undefined0.51 undefined0.47 undefined
20181.5 undefined0.44 undefined0.37 undefined
20171.2 undefined0.37 undefined0.31 undefined
20161.05 undefined0.35 undefined0.29 undefined

Hansoh Pharmaceutical Group Company business model

The Hansoh Pharmaceutical Group Co Ltd is a leading company in the pharmaceutical industry in China. It was founded in 1995 and has its headquarters in Lianyungang, with branches in Beijing and Shanghai. The company specializes in developing and producing innovative drugs for various diseases. It invests significant resources in research and development, collaborating with renowned research institutes and universities. Hansoh has a wide range of products in areas such as oncology, anesthesia, antibiotics, anti-infectives, and cardiovascular diseases. It has expanded its research and development activities in recent years and has partnerships with other pharmaceutical companies. The company mainly sells its products to hospitals and medical facilities in China. It is committed to strong corporate governance and sustainability, and it has been recognized for its environmental initiatives. Overall, Hansoh Pharmaceutical Group Co Ltd is a major player in the Chinese pharmaceutical industry. Hansoh Pharmaceutical Group Company is one of the most popular companies on Eulerpool.com.

Hansoh Pharmaceutical Group Company SWOT Analysis

Strengths

1. Established Brand Reputation: Hansoh Pharmaceutical Group Co Ltd has built a strong brand image in the pharmaceutical industry, known for its high-quality and reliable products.

2. Diverse Product Portfolio: The company offers a wide range of pharmaceutical products across various therapeutic areas, catering to diverse customer needs.

3. Strong Research and Development Capabilities: Hansoh invests significantly in research and development, leading to continuous innovation and the introduction of new drugs to the market.

4. Extensive Distribution Network: With an extensive distribution network, the company can reach a vast customer base, both domestically and internationally.

Weaknesses

1. Dependency on Key Products: Hansoh Pharmaceutical Group Co Ltd relies heavily on a few key products for a significant portion of its revenue, making it vulnerable to fluctuations in demand or patent expirations.

2. Limited Global Presence: While the company has expanded its international reach, it still has a relatively limited global presence compared to some of its competitors.

3. Regulatory Challenges: Operating in the pharmaceutical industry involves navigating strict regulations, which can pose challenges and delays in product approvals and market entry.

Opportunities

1. Growing Healthcare Market: The increasing demand for healthcare services, particularly in emerging markets, presents an opportunity for Hansoh Pharmaceutical to expand its customer base and revenue.

2. Emerging Technologies: Advances in technology, such as personalized medicine and digital health solutions, open up avenues for innovation and the development of new products and services.

3. Strategic Partnerships and Collaborations: Collaborating with other pharmaceutical companies, research institutions, or technology firms can enhance Hansoh's capabilities and accelerate its growth.

Threats

1. Intense Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous established players and new entrants vying for market share.

2. Stringent Regulatory Environment: Regulatory changes or compliance issues can impact the company's operations, requiring significant resources and potentially affecting profitability.

3. Patent Expirations and Generic Competition: The expiration of patents for key drugs can lead to increased competition from generic alternatives, potentially eroding Hansoh's market share and revenue.

Hansoh Pharmaceutical Group Company Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Hansoh Pharmaceutical Group Company historical P/E ratio, EBIT multiple, and P/S ratio

Hansoh Pharmaceutical Group Company shares outstanding

The number of shares was Hansoh Pharmaceutical Group Company in 2023 — This indicates how many shares 6.02 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hansoh Pharmaceutical Group Company earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hansoh Pharmaceutical Group Company's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hansoh Pharmaceutical Group Company’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hansoh Pharmaceutical Group Company's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hansoh Pharmaceutical Group Company dividend history and estimates

In 2023, Hansoh Pharmaceutical Group Company paid a dividend amounting to 0.19 CNY. Dividend means that Hansoh Pharmaceutical Group Company distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Hansoh Pharmaceutical Group Company provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Hansoh Pharmaceutical Group Company’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Hansoh Pharmaceutical Group Company's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Hansoh Pharmaceutical Group Company Dividend History

DateHansoh Pharmaceutical Group Company Dividend
2029e0.2 undefined
2028e0.2 undefined
2027e0.2 undefined
2026e0.21 undefined
2025e0.2 undefined
2024e0.21 undefined
20230.19 undefined
20220.23 undefined
20210.08 undefined

Hansoh Pharmaceutical Group Company dividend payout ratio

In 2023, Hansoh Pharmaceutical Group Company had a payout ratio of 35.1%. The payout ratio indicates the percentage of the company's profits that Hansoh Pharmaceutical Group Company distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Hansoh Pharmaceutical Group Company represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Hansoh Pharmaceutical Group Company could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Hansoh Pharmaceutical Group Company's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Hansoh Pharmaceutical Group Company Payout Ratio History

DateHansoh Pharmaceutical Group Company Payout ratio
2029e37.8 %
2028e38.6 %
2027e37.72 %
2026e37.07 %
2025e41 %
2024e35.1 %
202335.1 %
202252.78 %
202117.43 %
202035.1 %
201935.1 %
201835.1 %
201735.1 %
201635.1 %
Unfortunately, there are currently no price targets and forecasts available for Hansoh Pharmaceutical Group Company.

Eulerpool ESG Scorecard© for the Hansoh Pharmaceutical Group Company stock

Eulerpool World ESG Rating (EESG©)

87/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

63

Environment

Scope 1 - Direct Emissions
10,546.85
Scope 2 - Indirect emissions from purchased energy
81,565.21
Scope 3 - Indirect emissions within the value chain
51,543.36
Total CO₂ emissions
92,112.06
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
✅
Water consumption and efficiency
✅

Social

Percentage of female employees37.553
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Hansoh Pharmaceutical Group Company shareholders

%
Name
Stocks
Change
Date
65.71924 % Zhong (Huijuan)3,900,000,00004/29/2023
16.00853 % Cen (Junda)950,000,00009/1/2023
1.92045 % Fidelity Management & Research Company LLC113,965,69511,777,8672/29/2024
0.52817 % The Vanguard Group, Inc.31,343,444-360,0003/31/2024
0.50107 % FIL Investment Management (Hong Kong) Limited29,735,359-1,757,5552/29/2024
0.46380 % UBS Asset Management (Hong Kong) Limited27,523,481-22,00012/31/2023
0.40531 % BlackRock Institutional Trust Company, N.A.24,052,609-250,0003/31/2024
0.34882 % Federated Hermes International20,700,249243,56812/31/2023
0.34200 % FIL Investment Management (Singapore) Ltd.20,295,197-2,810,0232/29/2024
0.32071 % Bosera Asset Management Co., Ltd.19,032,0004,672,00012/31/2023
1
2
3
4
5
...
10

Hansoh Pharmaceutical Group Company Executives and Management Board

Ms. Yuan Sun36
Hansoh Pharmaceutical Group Company Executive Director (since 2015)
Compensation 11.18 M
Ms. Huijuan Zhong62
Hansoh Pharmaceutical Group Company Chief Executive Officer, Executive Chairlady of the Board (since 2015)
Compensation 11.14 M
Mr. Aifeng Lyu46
Hansoh Pharmaceutical Group Company Executive Director (since 2016)
Compensation 9.72 M
Mr. Sheung Wai Chan69
Hansoh Pharmaceutical Group Company Non-Executive Independent Director
Compensation 360,000
Mr. Guoqiang Lin80
Hansoh Pharmaceutical Group Company Non-Executive Independent Director
Compensation 360,000
1
2
3

Most common questions regarding Hansoh Pharmaceutical Group Company

What values and corporate philosophy does Hansoh Pharmaceutical Group Company represent?

Hansoh Pharmaceutical Group Co Ltd represents values of innovation, quality, and patient-centricity. With a strong corporate philosophy, the company focuses on developing and delivering high-quality pharmaceutical products that improve and save lives. Hansoh Pharmaceutical Group Co Ltd's commitment to innovation drives the development of new and effective therapies to address unmet medical needs. The company's patient-centric approach ensures that their products are developed and manufactured with the highest quality standards, aiming to provide optimal healthcare solutions for patients worldwide. Hansoh Pharmaceutical Group Co Ltd's dedication to excellence makes them a trusted and reliable player in the pharmaceutical industry.

In which countries and regions is Hansoh Pharmaceutical Group Company primarily present?

Hansoh Pharmaceutical Group Co Ltd is primarily present in China.

What significant milestones has the company Hansoh Pharmaceutical Group Company achieved?

Hansoh Pharmaceutical Group Co Ltd has achieved several significant milestones. In recent years, the company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a major milestone in its financial development. Additionally, Hansoh Pharmaceutical Group has made significant advancements in its research and development efforts, resulting in the successful launch of innovative and high-quality pharmaceutical products. The company has also expanded its global footprint by establishing strategic collaborations and partnerships with international pharmaceutical companies. Overall, Hansoh Pharmaceutical Group Co Ltd continues to make notable strides in the pharmaceutical industry, solidifying its position as a leading player in the market.

What is the history and background of the company Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Co Ltd is a leading pharmaceutical company with a rich history and background. Founded in 1995, the company has rapidly grown to become one of the largest and most respected pharmaceutical companies in China. Hansoh Pharmaceutical focuses on the research, development, manufacturing, and commercialization of innovative drugs in various therapeutic areas like oncology, diabetes, and cardiovascular diseases. With a strong emphasis on innovation and quality, Hansoh Pharmaceutical has successfully introduced numerous blockbuster drugs, gaining recognition both domestically and internationally. The company's commitment to excellence and patient care has established it as a trusted name in the pharmaceutical industry.

Who are the main competitors of Hansoh Pharmaceutical Group Company in the market?

The main competitors of Hansoh Pharmaceutical Group Co Ltd in the market include well-known pharmaceutical companies such as Shanghai Pharmaceuticals Holding Co Ltd, Jiangsu Hengrui Medicine Co Ltd, and Sino Biopharmaceutical Ltd. These companies compete with Hansoh Pharmaceutical Group Co Ltd in terms of research and development, product portfolio, market presence, and overall performance in the pharmaceutical industry.

In which industries is Hansoh Pharmaceutical Group Company primarily active?

Hansoh Pharmaceutical Group Co Ltd primarily operates in the pharmaceutical industry.

What is the business model of Hansoh Pharmaceutical Group Company?

The business model of Hansoh Pharmaceutical Group Co Ltd is focused on research, development, manufacturing, and commercialization of innovative pharmaceutical products. As one of the leading pharmaceutical companies in China, Hansoh Pharmaceutical Group Co Ltd aims to provide high-quality and affordable medications to improve the well-being of individuals. The company collaborates with healthcare professionals and institutions to meet the evolving healthcare needs of patients. Hansoh Pharmaceutical Group Co Ltd's business model emphasizes continuous innovation, leveraging cutting-edge technology, and maintaining strong partnerships across the industry. Through its diversified portfolio and commitment to excellence, the company strives to contribute to the advancement of healthcare in China and globally.

What is the P/E ratio of Hansoh Pharmaceutical Group Company 2024?

The Hansoh Pharmaceutical Group Company P/E ratio is 31.86.

What is the P/S ratio of Hansoh Pharmaceutical Group Company 2024?

The Hansoh Pharmaceutical Group Company P/S ratio is 9.85.

What is the Quality Investing of Hansoh Pharmaceutical Group Company?

The Quality Investing for Hansoh Pharmaceutical Group Company is 3/10.

What is the revenue of Hansoh Pharmaceutical Group Company 2024?

The expected Hansoh Pharmaceutical Group Company revenue is 12.32 B CNY.

How high is the profit of Hansoh Pharmaceutical Group Company 2024?

The expected Hansoh Pharmaceutical Group Company profit is 3.81 B CNY.

What is the business model of Hansoh Pharmaceutical Group Company

Hansoh Pharmaceutical Group Co Ltd is a leading Chinese pharmaceutical company specializing in research, development, production, and distribution of innovative and generic drugs. The company originated in Jiangsu province, China and operates globally today. The business model of Hansoh consists of various divisions focusing on drug development, manufacturing, distribution, and marketing. The company has a strong presence in the Asian market and is expanding its business worldwide. The divisions of Hansoh include research and development of new drugs, generics, over-the-counter products, and biological drugs. The company is renowned for its capabilities in active ingredient research, development, and manufacturing. Hansoh's products cover a wide range of therapeutic areas including oncology, cardiology, neurology, and infectious diseases. In the research and development field, Hansoh drives growth through investments in cutting-edge technologies like new drug research in collaboration with universities and research institutes, artificial intelligence and big data, as well as close cooperation with other companies. The generics division is a crucial part of Hansoh's business model. The company offers a wide range of generics, providing a cost-effective yet effective alternative to expensive brand-name products. The company works towards lowering production costs in the long term and facilitating access to medication for patients worldwide. Additionally, the company operates in the over-the-counter (OTC) sector, offering products such as vitamins, pain relievers, and non-prescription medications. Hansoh also focuses heavily on biological drugs, particularly in the field of antibody therapy. Here, the company works on developing new drugs for the treatment of cancer and other serious illnesses. To make Hansoh Pharma's business successful, the company has established a strong presence in key markets around the world. Collaboration with other pharmaceutical companies to jointly market and distribute their products is a crucial aspect. For example, Germany and the USA are important markets for the company. Overall, the business model of Hansoh Pharmaceutical Group Co Ltd is focused on the long-term sustainability and growth of their business. Through a combination of innovative development and production processes, a broad portfolio of drugs, and a strong presence in key markets worldwide, the company remains on a growth trajectory and will establish itself as a significant player in the global pharmaceutical industry in the future.

What is the Hansoh Pharmaceutical Group Company dividend?

Hansoh Pharmaceutical Group Company pays a dividend of 0.23 CNY distributed over payouts per year.

How often does Hansoh Pharmaceutical Group Company pay dividends?

The dividend cannot currently be calculated for Hansoh Pharmaceutical Group Company or the company does not pay out a dividend.

What is the Hansoh Pharmaceutical Group Company ISIN?

The ISIN of Hansoh Pharmaceutical Group Company is KYG549581067.

What is the Hansoh Pharmaceutical Group Company WKN?

The WKN of Hansoh Pharmaceutical Group Company is A2PLRC.

What is the Hansoh Pharmaceutical Group Company ticker?

The ticker of Hansoh Pharmaceutical Group Company is 3692.HK.

How much dividend does Hansoh Pharmaceutical Group Company pay?

Over the past 12 months, Hansoh Pharmaceutical Group Company paid a dividend of 0.19 CNY . This corresponds to a dividend yield of about 0.95 %. For the coming 12 months, Hansoh Pharmaceutical Group Company is expected to pay a dividend of 0.2 CNY.

What is the dividend yield of Hansoh Pharmaceutical Group Company?

The current dividend yield of Hansoh Pharmaceutical Group Company is 0.95 %.

When does Hansoh Pharmaceutical Group Company pay dividends?

Hansoh Pharmaceutical Group Company pays a quarterly dividend. This is distributed in the months of October, July, October, October.

How secure is the dividend of Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Company paid dividends every year for the past 0 years.

What is the dividend of Hansoh Pharmaceutical Group Company?

For the upcoming 12 months, dividends amounting to 0.2 CNY are expected. This corresponds to a dividend yield of 1.01 %.

In which sector is Hansoh Pharmaceutical Group Company located?

Hansoh Pharmaceutical Group Company is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hansoh Pharmaceutical Group Company kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hansoh Pharmaceutical Group Company from 10/30/2024 amounting to 0.03 CNY, you needed to have the stock in your portfolio before the ex-date on 9/24/2024.

When did Hansoh Pharmaceutical Group Company pay the last dividend?

The last dividend was paid out on 10/30/2024.

What was the dividend of Hansoh Pharmaceutical Group Company in the year 2023?

In the year 2023, Hansoh Pharmaceutical Group Company distributed 0.23 CNY as dividends.

In which currency does Hansoh Pharmaceutical Group Company pay out the dividend?

The dividends of Hansoh Pharmaceutical Group Company are distributed in CNY.

All fundamentals about Hansoh Pharmaceutical Group Company

Our stock analysis for Hansoh Pharmaceutical Group Company Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hansoh Pharmaceutical Group Company Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.